HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Circulating biomarkers of cognitive decline and dementia.

Abstract
Plasma and serum biochemical markers proposed for cognitive decline of degenerative (Alzheimer's disease, AD) or vascular origin and predementia syndromes (mild cognitive impairment and other related entities) are based on pathophysiologic processes such as lipoprotein metabolism (total cholesterol, apolipoprotein E, 24S-hydroxy-cholesterol), and vascular disease (homocysteine, lipoprotein(a)); SP formation (amyloid beta(Abeta)-protein, Abeta autoantibodies, platelet APP isoforms), oxidative stress (isoprostanes, vitamin E), and inflammation (cytokines). This review will focus on the current knowledge on circulating serum and plasma biomarkers of cognitive decline and dementia that are linked to cholesterol homeostasis and lipoprotein abnormalities, senile plaque formation and amyloid precursor protein (APP) metabolism, oxidative stress, and inflammatory reactions. Special emphasis will, however, be placed on biomarkers related to lipoprotein metabolism and vascular disease. Analytically, most plasma and serum proteins or metabolites lack reproducibility, sensitivity, or specificity for the diagnosis, risk and progression assessment, or therapeutic monitoring of AD and other dementing disorders. Measures linked to lipoprotein metabolism and vascular disease, APP metabolism, oxidative stress, or inflammation appear altered in AD relative to controls, but lack sufficient discriminatory power. Measures combining several biomarkers or incorporating a range of proteins in plasma and small molecule metabolites are promising approaches for the development of plasma or serum-based diagnostic tests for AD and other dementing disorders, as well as for predementia syndromes.
AuthorsVincenzo Solfrizzi, Alessia D'Introno, Anna Maria Colacicco, Cristiano Capurso, Orlando Todarello, Vincenza Pellicani, Sabrina A Capurso, Giuseppe Pietrarossa, Vito Santamato, Antonio Capurso, Francesco Panza
JournalClinica chimica acta; international journal of clinical chemistry (Clin Chim Acta) Vol. 364 Issue 1-2 Pg. 91-112 (Feb 2006) ISSN: 0009-8981 [Print] Netherlands
PMID16139826 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Amyloid beta-Peptides
  • Biomarkers
  • Cholesterol, HDL
  • Hydroxycholesterols
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • 24-hydroxycholesterol
  • Cholesterol
Topics
  • Amyloid beta-Peptides (blood)
  • Biomarkers (blood)
  • Cholesterol (blood)
  • Cholesterol, HDL (blood)
  • Cognition Disorders (blood, diagnosis)
  • Dementia (blood, diagnosis)
  • Humans
  • Hydroxycholesterols (blood)
  • Peptide Fragments (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: